RXRA and acute myeloid leukemia: Preliminary results from our laboratory suggest that NHRs such as PPARG and RXRA were downregulated in chemoresistant acute myeloid leukemia (AML) cell lines (Karathedath et al., 2013), suggesting that NHRs can be modulated to improve chemosensitivity.